FemTech spans a broad spectrum of long overdue solutions addressing women’s health, from connected devices to digital health platforms and data-driven care tools. It is a historically underserved market, that operates at the intersection of evolving healthcare, AI and privacy laws and regulation, each with distinct nuances, costs and operational demands. Although this creates complexity and raises barriers to entry, it also creates opportunity and advantage for companies and investors that navigate the legal landscape well.
While the Israeli ecosystem continues to foster and produce exceptional innovation, the local market is too small on its own to be commercially attractive, and most Israeli FemTech start-ups look to the US and Europe as their primary target markets.
Regulatory Pathways
For founders and investors alike, one of the earliest legal questions is whether a FemTech product constitutes a medical device, including SaMD or SiMD. Fertility trackers, digital diagnostic tools and wearable health monitors may all be captured, particularly where they diagnose, treat or prevent health conditions. Getting the regulatory analysis right from the outset is critical. It influences product design, financing requirements and go-to-market strategy.
FemTech products that qualify as medical devices are subject to market-specific regulation, including FDA requirements in the US and CE marking in the EU, alongside separate regimes in jurisdictions such as the UK and Switzerland. Although approvals, clinical testing and documentation can be demanding, companies that address these issues early are generally better positioned to build trust, scale responsibly and present a more investable profile.
For investors, this is a core diligence issue, but also a familiar one. A well-designed regulatory strategy can unlock access to major markets, reduce risk and materially enhance enterprise value. At the same time, where a product does not qualify as a medical device, disciplined advertising and marketing practices remain essential, because unsubstantiated medical claims can create material legal and commercial risk.
Israel’s regulatory environment for medical devices has become more business-friendly. Medical devices can now benefit from three streamlined registration pathways:
- A Declaration Route for low-risk Class I devices, allowing immediate self-declaration registration within 48 hours.
- A Fast-Track Route for moderate-risk Class II/IIa/IIb devices, with 45-60 business-day review periods where prior approval exists in recognized reference countries.
- A Normal Route for high-risk devices, with approximately 120-day reviews.
These reforms reflect Israel’s adoption of a “reliance” model, under which approvals from the US, EU, Canada, Australia, the UK, Switzerland and other recognized jurisdictions can significantly shorten time to market while preserving safety standards. That translates into a potentially more efficient path to commercialization.
This medical device reform forms part of Israel’s broader “What’s Good for Europe is Good for Israel” standards harmonization initiative, effective as of January 1, 2025. The initiative aligns Israeli import standards with European directives and regulations across multiple product categories, with the aim of lowering barriers, increasing competition and simplifying processes.
Additional standards, including in relation to medical devices, took effect in Israel in July 2025. For FemTech companies and their investors, the message is clear: Israel is moving toward a more globally aligned and commercially practical framework that can support faster deployment and cross-border growth.
The Israeli Ministry of Health has also launched, together with the Israel Innovation Authority, a regulatory sandbox for 2025-2026 to support breakthrough AI healthcare technologies. By offering a controlled testing environment with active regulatory guidance, the sandbox may help FemTech companies refine products more quickly, engage with regulators earlier and reduce uncertainty around new advanced autonomous medical systems. For investors, this may provide an additional channel for de-risking innovation at an earlier stage.
Reimbursement can be a major commercial inflection point for a FemTech start-up. In a high-cost healthcare environment, FemTech solutions classified as medical devices are generally more likely than wellness products to qualify for coverage under insurance and public health frameworks, and that qualification can make or break a product.
In Israel, the annual national health basket update process is particularly significant. Technologies included in the basket are more readily adopted by the country’s four HMOs, which function as both insurers and providers. Reimbursement strategy is therefore not merely a regulatory issue. It can be central to market penetration, revenue generation and long-term investor returns.
FemTech companies that offer medical advice or provider-facing care models must also consider healthcare delivery rules, including the US corporate practice of medicine doctrine and state-by-state licensing requirements. These issues are especially relevant for telemedicine-enabled platforms. While they add structural complexity, they are manageable with the right legal architecture and are best viewed as core diligence and execution items rather than barriers to investment.
Artificial Intelligence (AI)
FemTech innovation is advancing in parallel with a rapidly evolving AI regulatory landscape, including the EU AI Act, US state-level initiatives and sector-specific guidance from bodies such as the FTC, FDA and WHO, as well as market standards such as the NIST AI Risk Management Framework and ISO/IEC 42001.
These frameworks emphasize transparency, explainability, robustness, security, accountability, human oversight and fairness. For companies operating in FemTech, these principles matter because products often address sensitive conditions, vulnerable users and high-impact decisions.
At the same time, AI is one of the key reasons investors are paying attention to FemTech. Used well, it can enable better personalization, earlier detection, smarter monitoring and broader access to care in historically underserved areas.
AI can also help detect and correct the long-standing bias in research and product design that has too often been built around male datasets and male clinical assumptions. Conversely, if AI systems are trained on incomplete, unrepresentative or historically biased data, they may replicate or even exacerbate inequities affecting women across lines of sex, race, sexual orientation and socioeconomic background, potentially creating litigation, regulatory and reputational exposure.
Companies that build responsibly, using representative data and strong governance, are therefore better positioned to generate both commercial value and meaningful market differentiation.
Privacy and Data Security
FemTech solutions often rely on highly sensitive personal data, including data relating to reproductive health, gender, sexuality, menstrual cycles, biometric markers and genetics. Companies in this sector must navigate stringent privacy, cybersecurity and data protection rules, including the GDPR in Europe, HIPAA in the United States and a growing patchwork of US state laws such as the California Privacy Rights Act.
Compliance requires more than baseline disclosures. It calls for appropriate security controls, valid consent mechanisms, disciplined marketing practices, restrictions on use of tracking technologies and cookies, and clear internal governance around what data is collected, how it is used and why.
Special focus must be given to the rights of data subjects to access, correct and erase their data, and data loss or exposure in a data breach may trigger notification obligations to regulatory authorities and affected individuals. In a market using deeply intimate data, user trust can directly influence adoption, retention and brand value, and privacy and security compliance and strong practices can be a genuine competitive advantage, rather than merely a legal necessity.
Intellectual Property
For many healthcare start-ups, a substantial portion of their value lies in intellectual property, and FemTech is no exception. Protecting patents, trade secrets and branding is critical. Although securing patents and trademarks rights across multiple jurisdictions can be costly and operationally demanding, the cost of not doing so may be far greater in the long run.
The issue is pertinent where AI is involved. Determining the rightful owner of AI-driven insights and outputs remains particularly complex – does the creation vest in the provider of the data or the start-up that wrote the algorithm? The absence of uniform, definitive legal answers to this novel question poses a significant challenge, and can become a diligence and valuation issue.
Many breakthrough medical and FemTech solutions originate in academia, hospitals or clinical settings, where institutions seek to vigilantly protect their IP ownership and commercialization rights. Clear analysis of whether key IP was conceived during employment or institutional engagement is essential, and where ownership does not sit with the company, a robust and comprehensive license may be critical. For investors, clean IP rights are not a legal formality, they can be the foundation for value and exit opportunities.
In the high-demand, low-competition FemTech sector, the legal and regulatory hurdles are real, but they are neither unusual nor insurmountable. They are the kinds of challenges routinely managed across MedTech, digital health and AI businesses, and they can create meaningful barriers to entry for less-prepared competitors.
For founders, the opportunity is to build solutions that address pressing unmet needs and correct the outdated one-size-fits-all approach to healthcare.
For investors, the opportunity is to back a category with substantial room for innovation, and with a scalable and significant market addressing the health needs of roughly half the world’s population. As capital continues to recognize the power of the she-economy and the scale of unmet demand in women’s health, FemTech stands out as a compelling investment opportunity in modern healthcare.
***
Authors: Ariella Dreyfuss (M&A and Tech); Dr. Avishay Klein and Masha Yudashkin (Privacy, Data Protection, Cyber and AI); and Efrat Cohen (Regulatory Department)